Rochlin Kate 4
4 · IN8BIO, INC. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
IN8BIO (INAB) President Kate Rochlin Receives 80,000-Share Award
What Happened
Kate Rochlin, President and Chief Operating Officer of IN8BIO (INAB), was granted a derivative award covering 80,000 shares on February 4, 2026. The grant is reported at $0.00 per share (no cash paid at grant). This was an award/option-style grant, not an open-market purchase or sale, so it does not represent immediate sale or transferable shares.
Key Details
- Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely file).
- Transaction type/code: A — Award/Grant (derivative security).
- Amount: 80,000 shares (derivative); reported price $0.00.
- Vesting (footnote): 25% vests on February 4, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- No 10b5-1 plan or tax-withholding note disclosed in the provided details.
Context
This is a standard equity compensation award to an executive and represents future potential ownership subject to vesting and continued employment. Because it is a derivative grant (option/award) with a multi-year vesting schedule, it is not an immediate market signal like a buy or sale; it primarily reflects standard executive compensation practices.
Insider Transaction Report
- Award
Employee Stock Option (right to buy)
[F1]2026-02-04+80,000→ 80,000 totalExercise: $1.96Exp: 2036-02-04→ Common Stock (80,000 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.